Skip to main content

Table 2 Efficacy and safety outcomes in patients who underwent PCI at baseline with those who did not undergo PCI

From: Insights from Egyptian ticagrelor study in patients who presented with acute coronary syndrome (ETS in ACS)

  PCI No PCI P value
Number (%) 401 (48.3) 429 (51.7)  
Composite primary endpoints (n) 14 14 0.931
Secondary efficacy endpoints (n) 62 65 0.946
Cardiovascular death (n) 4 6 0.348
Myocardial infarction (n) 5 2 0.234
Stroke (n) 7 4 0.328
Hospitalization for UA (n) 33 34 0.879
Urgent revascularization (n) 22 10 0.027
TIMI major bleeding (n) 9 1 0.009
TIMI minor bleeding (n) 71 39 0.002
Intracranial hemorrhage (n) 2 0 0.149
Dyspnea (n) 64 38 0.004
Bradycardia (n) 20 6 0.002